Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
Abstract
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are associated with a decrease in blood pressure (BP) levels. BP reduction was confirmed using 24-h ambulatory blood pressure monitoring in the EM...
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
- Diabetes mellitus: an important risk factor for peripheral vascular disease
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.